azn201305026k.htm
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of May 2013

 
Commission File Number: 001-11960

 
AstraZeneca PLC
 
 
2 Kingdom Street, London W2 6BD
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X      Form 40-F __
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______           
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
Yes __     No X
 
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 

 
 

Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
 
 
On 1 May 2013, the interest of Mene Pangalos, a person discharging managerial responsibilities, in AstraZeneca PLC Ordinary Shares of $0.25 each changed as detailed below. 
 
The change in interest relates to the vesting of an award of 8,319 shares made in May 2010 under the AstraZeneca Restricted Share Plan. In accordance with the terms of the award, Mr Pangalos has become beneficially entitled to these shares
 
Following certain tax deductions, Mr Pangalos has received 4,409 shares into a personal brokerage account.
 
For tax purposes, the fair market value of the shares at vest was 3342.5 pence per share being the closing price of AstraZeneca ordinary shares on the last trading day preceding the vesting day.
 
 
A C N Kemp
Company Secretary
2 May 2013
 
 
 
  
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
Date: 02 May 2013
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary